What's happening
This bill creates a wholesale prescription drug importation program in New York to allow safe, cost-saving drug imports from other countries.
Why it matters
Focuses on Safety and Regulatory Compliance. The bill requires that only prescription drugs meeting U.S. FDA standards are imported, and mandates rigorous tracking and tracing of all imported medications to maintain drug safety and integrity.
Potential for Significant Consumer Savings. Only drugs expected to generate substantial savings for New York consumers will be imported, aiming to directly address high prescription drug costs in the state.
Oversight, Accountability, and Anti-Monopoly Measures. The program includes annual audits, mandatory reporting to legislative committees, and specific provisions for monitoring and preventing anticompetitive behavior, helping to ensure transparency and fair market practices.
Integration With Federal Programs. The bill seeks to maximize participation by entities in the federal 340B drug pricing program without jeopardizing their eligibility, potentially expanding access to affordable drugs for vulnerable populations and safety-net providers.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Prescription drug wholesalers
Approved wholesalers could seek federal permission to import drugs for wholesale distribution within New York, subject to tracking requirements, reporting, audits and possible annual fees.
New Yorkers who use prescription drugs
The program would limit imports to drugs expected to generate substantial consumer savings and require audits to verify those savings.
Entities enrolled in or eligible for the federal 340B drug pricing program
The health commissioner would seek federal approvals to let them participate as fully as possible without jeopardizing their 340B eligibility.
- Watching
New York State Department of Health and attorney general
The department would develop and oversee the program, while the commissioner would consult with the attorney general to identify and monitor potential anticompetitive behavior.
Headline styles
Import Cheaper Prescription Drugs
Plain English, a few words. Used as the page title.
Sponsors
38 Co-sponsors
- Charles Barron
- Kevin Cahill
- Vivian Cook
- Jeffrey Dinowitz
- Steven Englebright
- Sandy Galef
- Aileen Gunther
- Pamela J. Hunter
- Charles Lavine
- William Magnarelli
- Michael Montesano
- Philip Ramos
- Jose Rivera
- Linda Rosenthal
- Rebecca Seawright
- Jo Anne Simon
- Kenneth Zebrowski
- Jonathan Jacobson
- Albert A. Stirpe
- Andrew Hevesi
- Robert C. Carroll
- John K. Mikulin
- Karines Reyes
- Michael Benedetto
- Catalina Cruz
- Harvey Epstein
- William Colton
- Yuh-Line Niou
- Amy Paulin
- Michaelle C. Solages
- Gina Sillitti
- Kimberly Jean-Pierre
- Thomas Abinanti
- John T. McDonald III
- Jessica Gonzalez-Rojas
- Doug Smith
- Phara Souffrant Forrest
- Chantel Jackson
3 Multi-sponsors
History
- Referred to higher education
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Import Cheaper Prescription Drugs
In Assembly Committee · Higher Education · Sponsor James Skoufis
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
133
2021-2022 Regular Sessions
IN ASSEMBLY (Prefiled)
January 6, 2021
Introduced by M. of A. GOTTFRIED, BARRON, CAHILL, COOK, DINOWITZ, ENGLE- BRIGHT, GALEF, GUNTHER, HUNTER, LAVINE, MAGNARELLI, MONTESANO, RAMOS, J. RIVERA, L. ROSENTHAL, SEAWRIGHT, SIMON, ZEBROWSKI, JACOBSON, STIRPE, HEVESI, CARROLL, MIKULIN, REYES, BENEDETTO, CRUZ, EPSTEIN, COLTON, NIOU -- Multi-Sponsored by -- M. of A. BUTTENSCHON, LUPARDO, THIELE -- read once and referred to the Committee on Higher Education
AN ACT to amend the public health law, in relation to creating a wholesale prescription drug importation program
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Title 2 of article 2-A of the public health law is amended by adding a new section 280-d to read as follows:
§ 280-d. Wholesale prescription drug importation program. 1. (a) There is hereby created in the department a wholesale prescription drug importation program.
(b) As used in this section, unless the context clearly requires otherwise, the following terms shall have the following meanings:
(i) "Wholesale prescription drug importation program" or "program" means the wholesale prescription drug importation program created under this section.
(ii) "Prescription drug wholesaler" means an entity authorized to acquire prescription drugs and sell or distribute them wholesale in the state.
(iii) "Approved wholesaler" means a prescription drug wholesaler approved under this section to participate in the program.
(c) The commissioner shall develop and implement the program in consultation with interested stakeholders and appropriate federal officials. The program shall comply with applicable federal requirements, including 21 U.S.C. § 384, and requirements regarding safety and cost savings. Under the program:
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00370-01-1
A. 133 2
(i) the commissioner shall approve one or more prescription drug wholesalers to seek federal certification and approval to import prescription drugs from one or more other countries, to be sold or distributed wholesale in the state;
(ii) prescription drugs shall only be acquired from suppliers regulated and authorized under the laws of the other country or a jurisdiction thereof;
(iii) only prescription drugs meeting the U.S. Food and Drug Administration's safety, effectiveness, and other standards shall be imported under the program;
(iv) only prescription drugs expected to generate substantial savings for consumers shall be imported;
(v) the approved wholesaler shall at all times comply with the tracking and tracing requirements of 21 U.S.C. §§ 360eee and 360eee-1 to the extent feasible and practical, including prior to imported prescription drugs coming into its possession;
(vi) an approved wholesaler shall not sell or distribute prescription drugs imported under the program outside the state;
(vii) the commissioner may impose an annual fee on approved wholesalers, which may be based in whole or in part on the value of prescription drugs imported by the approved wholesaler under the program, to support the operation of the program;
(viii) every approved wholesaler shall provide the commissioner with information on its participation in the program as reasonably required by the commissioner; the commissioner may provide for keeping certain information confidential within the department where reasonably necessary for successful operation of the program; and
(ix) the commissioner shall provide for auditing of the program, including making sure that prescription drugs are made available at substantial savings to consumers as a result of the program.
(d) The commissioner shall make regulations and take other actions reasonably necessary to implement the program.
2. The commissioner shall consult with the attorney general to identify the potential for, and to monitor, anticompetitive behavior under or in relation to the program.
3. (a) The commissioner shall seek all necessary approvals and certification by the secretary of the U.S. Department of Health and Human Services or other appropriate federal officials or agencies for the wholesale prescription drug importation program.
(b) The commissioner shall seek the appropriate federal approvals, waivers, exemptions, or agreements, or a combination thereof, as needed to enable all covered entities enrolled in or eligible for the federal 340B drug pricing program to participate in the wholesale prescription drug importation program to the fullest extent possible without jeopardizing their eligibility for the 340B program.
4. The commissioner shall establish procedures for prescription drug wholesalers to apply and be approved to be an approved wholesaler, including requirements for periodic renewal of that approval. The commissioner shall provide reasonable grounds for suspending or revoking approval of an approved wholesaler under this section, including reasonable provision for notice, opportunity to be heard, and appeal.
5. The commissioner shall annually report to the assembly committees on health and on ways and means and the senate committees on health and on finance regarding the operation of the wholesale prescription drug importation program.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.